Document is current
Any future updates will be listed below
-
Authors
Mamez, Anne-Claire https://orcid.org/0000-0002-8666-7089
Pradier, Amandine
Morin, Sarah
Giannotti, Federica
Bernardi, Chiara
Masouridi-Levrat, Stavroula
Chalandon, Yves https://orcid.org/0000-0001-9341-8104
Simonetta, Federico
- License Information
-
More Information
Article History
Received: 10 July 2024
Revised: 22 October 2024
Accepted: 29 October 2024
First Online: 15 November 2024
Competing interests
: ACM: nothing to disclose. AP: nothing to disclose. SM: nothing to disclose. FG: nothing to disclose. CB: research funding from BMS/Celgene. SML: nothing to disclose. YC: consulting fees for advisory board from MSD, Novartis, Incyte, BMS, Pfizer, Abbvie, Roche, Jazz, Gilead, Amgen, Astra-Zeneca, Servier, Pierre Fabre, Medac; Travel support from MSD, Roche, Gilead, Amgen, Incyte, Abbvie, Janssen, Astra-Zeneca, Jazz, Sanofi, Pierre Fabre all via the institution. FS: institutional consulting fees from BMS/Celgene, Incyte, Kite/Gilead; speaker fees from Kite/Gilead, Incyte; travel support from Kite/Gilead, Novartis, AstraZeneca, Neovii, Janssen; research funding from Kite/Gilead, Novartis, BMS/Celgene.
